Ligand to Participate in May Investor Conferences
Rhea-AI Summary
Ligand (Nasdaq: LGND) will have senior management participate in multiple investor conferences in May 2026, including virtual and in-person events. Management will give fireside chats and host one-on-one meetings at H.C. Wainwright, Bank of America, CJS Securities, RBC, Craig-Hallum, Benchmark, and others.
Investors seeking one-on-one meetings should contact their conference or broker representative to arrange sessions.
Positive
- None.
Negative
- None.
News Market Reaction – LGND
In the May 6 session, LGND gained 0.11%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 27 | Royalty acquisition | Positive | +4.5% | Agreed to acquire XOMA Royalty and raised 2026 revenue and EPS guidance. |
| Apr 22 | Earnings date notice | Neutral | -0.1% | Scheduled Q1 2026 results call and provided webcast and dial-in details. |
| Apr 14 | FDA approval | Positive | +8.8% | Partner Travere gained full FDA approval for FILSPARI with 9% royalty to Ligand. |
| Mar 26 | Team expansion | Positive | -0.4% | Announced senior hires and a promotion to strengthen business development team. |
| Mar 04 | Investor conferences | Neutral | +2.3% | Outlined March 2026 conference appearances and one-on-one meeting availability. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with clearly positive fundamentals has mostly seen aligned positive price reactions, with only one notable divergence on strategic hiring news.
Over the past few months, Ligand has reported several material developments. On April 27, 2026, it announced a $739 million XOMA Royalty acquisition and raised 2026 guidance, which coincided with a 4.55% gain. A partner’s full FDA approval for FILSPARI on April 14, 2026 saw shares rise 8.85%. Earlier “investor conferences” and corporate development updates in March produced smaller moves between about -0.42% and 2.31%. Today’s May conference participation fits that ongoing investor-outreach pattern.
AI-generated analysis. How Rhea-AI works. Not financial advice.
JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:
- H.C. Wainwright Royalty Company Conference (Virtual): Ligand CEO Todd Davis and Wes Kaupinen, president and CEO of Ligand portfolio company Palvella Therapeutics, will participate in a fireside chat at 9:30 a.m. ET on May 6, 2026.
- Bank of America Healthcare Conference (Las Vegas): Management will participate in a fireside chat at 4:20 p.m. PT on May 12, 2026 and be available for one-on-one meetings on May 12, 2026 and May 13, 2026.
- CJS Securities Spring 1x1 Conference (Virtual): Management will participate in one-on-one meetings on May 13, 2026.
- H.C. Wainwright BioConnect Investor Conference at Nasdaq (New York): Management will participate in a fireside chat at 9:30 a.m. ET on May 19, 2026 and be available for one-on-one meetings.
- RBC Capital Markets Global Healthcare Conference (New York): Management will participate in a fireside chat at 11:30 a.m. ET on May 20, 2026.
- Craig-Hallum Institutional Investor Conference (Minneapolis): Management will participate in one-on-one meetings on May 28, 2026.
- Benchmark Healthcare House Call Conference (Virtual): Management will participate in one-on-one meetings on May 28, 2026.
Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Bank of America, Benchmark, CJS Securities, Craig-Hallum, H.C. Wainwright, or RBC representative.
About Ligand
Ligand is a leading royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. Ligand owns and manages one of the largest and most diversified portfolios of biopharmaceutical royalties in the industry, with economic interests in more than 100 development and commercial-stage assets. Ligand funds high-value programs in exchange for long-term economic interests, aligning capital with clinical and commercial success. Ligand’s royalty portfolio is designed to deliver consistent and predictable revenue streams across a broad range of therapeutic assets. Ligand also licenses its proprietary technologies, Captisol® and NITRICIL™, to support drug development and formulation across its global partner network. For more information, visit www.ligand.com or follow Ligand on X and LinkedIn.
Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
